Consolidated gross margin for the second one fourth of 2011 was 56 percent compared to 49 percent in the similar prior year period. Cost of sales in the second quarter 2011 included around $0.7 million in noncash fair value changes for acquired AVR inventory. Sustained improvements in gross margin will be the result of favorable product mix, selected price boosts, higher usage of plant capacities and increased sales of higher margin items introduced in 2010 2010. Second quarter 2011 adjusted EBITDA was $10.6 million compared with $4.2 million in the comparable prior year quarter. Net gain for the second quarter of 2011 was $17.9 million, and earnings per share were $0.17 per diluted share compared to a net loss of $9.4 million and loss per share of $0.10 in the comparable prior year one fourth.In terms of medications, medicines in the stimulant course are known to be quite effective for dealing with ADHD. Types of stimulant medicines used to treat this problem include short-acting medicines like methylphenidate and dexmethylphenidate , intermediate-acting medicines like dextroamphetamine amphetamine , and long-acting stimulants like methylphenidate slow release , dexmethylphenidate , and lisdexamfetamine . However, for some individuals, the relative unwanted effects of the medicine prevent these medicines from being appropriate. Therefore, specific nonstimulant medicines, which are also approved by the U.S. Food and Drug Administration for effective treatment of ADHD, are recommended for those individuals. Types of nonstimulant medications include atomoxetine , guanfacine , and clonidine .